PMC4674012_01
The translocation t(9;22)(q34;q11) in bone marrow at diagnosis. Karyotype abnormality was revealed by cytogenetic analysis using standard G-banding technique: 46,XY,t(9;22)(q34;q11). The t(9;22)(q34;q11) was found in 20 metaphases at diagnosis. Two marker chromosomes are indicated by arrow: der9q and Ph'. Der indicates derivate, Ph' indicates Philadelphia chromosome, 22q-.
bmi-suppl.3-2015-043f1.jpg
PMC4674012_01_bmi-suppl.3-2015-043f1.jpg
f1-bmi-suppl.3-2015-043
Cytogenetic and molecular genetic analyses developed the presence of a translocation t(9;22) (q34;q11) (Fig. 1) and chimeric BCR-ABL mRNA transcripts.
Normal female karyotype after allo-SCT. Normal female donor karyotype was found in bone marrow cells after allo-SCT: 46,XX.
bmi-suppl.3-2015-043f2.jpg
PMC4674012_01_bmi-suppl.3-2015-043f2.jpg
f2-bmi-suppl.3-2015-043
From October 2011 to date, repeated cytogenetic and molecular genetic analyses demonstrated normal female donor karyotype (Fig. 2), complete donor chimerism, and no detected disease at the molecular level.
The monitoring of the patient's response to therapy. Responses of the patient to therapy with imatinib, dasatinib, and allo-SCT were estimated by BCR-ABL transcript levels. BCR-ABL were monitored using quantitative polymerase chain reaction either in the bone marrow or peripheral blood and expressed as the logarithmic ratio of BCR-ABL to the control gene ABL gene.
bmi-suppl.3-2015-043f3.jpg
PMC4674012_01_bmi-suppl.3-2015-043f3.jpg
f3-bmi-suppl.3-2015-043
The monitoring of the patient's response to therapy is demonstrated in Figure 3.